Cerebrolysin
Cerebrolysin is a multi-modal neuropeptide cocktail derived from standardized porcine brain protein hydrolysate, containing low-molecular-weight peptides (≤ 10,000 Da) with neurotrophic factor-like activity. It mimics the effects of endogenous neurotrophic factors including BDNF, GDNF, CNTF, NT-3, and IGF-1. In research settings, it is investigated for neurotrophic support, synaptic plasticity modulation, and neural recovery mechanisms in preclinical models of neurodegeneration and central nervous system injury.
Chemical Profile
| Property |
Value |
| CAS Number |
N/A (biologically-derived mixture) |
| Composition |
~80% low-molecular-weight peptides (≤ 10,000 Da), ~20% free amino acids |
| Active Components |
BDNF-like peptides, GDNF fragments, CNTF analogues, NT-3 mimetics, free amino acids |
| Molecular Weight Range |
120–10,000 Da (predominantly 500–3,000 Da) |
| Source |
Standardized porcine brain protein hydrolysate |
| Form |
Sterile isotonic solution (5 mL, 10 mL, 20 mL ampules) |
| Protein Content |
~50 mg of peptide fraction per mL |
Cerebrolysin at a Glance
- Class: Neurotrophic peptide cocktail
- Regulatory Status: Approved in 50+ countries (CNS indications)
- Research Status: Clinical (multiple Phase III/IV trials)
- Route: Intravenous (slow infusion), intramuscular
- Half-life: ~4–6 hours
- CAS: N/A (mixture)
- MW Range: 120–10,000 Da
- Key Feature: Multi-modal neurotrophic support
Mechanism of Action
Cerebrolysin exerts a multimodal mechanism of action that mimics and supports the activity of endogenous neurotrophic factors.
Primary Signaling Pathways
| Component |
Detail |
| BDNF/TrkB Activation |
Phosphorylates TrkB → ERK/MAPK → CREB signaling |
| GDNF Pathway |
Activates RET/GFRα → PI3K/Akt survival signaling |
| CNTF Pathway |
JAK/STAT3 activation → neuroprotective gene expression |
| NT-3/TrkC |
Supports neuronal survival and differentiation |
| IGF-1 Receptor |
Activates PI3K/Akt and MAPK pathways |
| NGF/TrkA |
Supports cholinergic neuron survival |
| Amyloid Modulation |
Reduces Aβ aggregation in neurodegeneration models |
Neurobiological Effects
| System |
Effect |
Mechanism |
| Neurogenesis |
Increases neural stem cell proliferation |
BDNF/CNTF-mediated |
| Synaptogenesis |
Promotes dendritic spine formation |
TrkB/TrkC signaling |
| Neuroprotection |
Reduces apoptosis, oxidative stress |
Akt pathway, antioxidant |
| Cerebral Blood Flow |
Improves microcirculation |
Endothelial protection |
| BBB Integrity |
Maintains blood-brain barrier function |
Tight junction protein regulation |
| Neurotransmitter Balance |
Modulates glutamatergic and cholinergic |
Calpain inhibition |
Pharmacology
| Parameter |
Value |
| Half-life (t½) |
~4–6 hours (IV) |
| Bioavailability (IM) |
~80% |
| Tmax |
~0.5–1 hour (IV infusion) |
| Volume of Distribution (Vd) |
~0.2 L/kg |
| Protein Binding |
Variable (peptide-dependent) |
| Metabolism |
Proteolytic cleavage (ubiquitous proteases) |
| Route |
Intravenous (slow infusion), intramuscular |
| Elimination |
Renal (amino acids and small peptides) |
| BBB Permeability |
~5–10% of peptide fraction crosses BBB |
Research Evidence
Dosing Reference
| Parameter |
Recommendation |
| Research Dose Range |
5–20 mL IV (2–10 mL IM) |
| Dosing Frequency |
3–7 times per week |
| Duration |
4–12 weeks (typically 20–30 injections per cycle) |
| Reconstitution |
Ready-to-use sterile solution |
| Infusion Rate |
Slow IV push (over 5–10 minutes) or IV drip (30–60 minutes) |
| Storage |
15–25°C (before opening); single use only |
Safety Profile
| Category |
Observations |
| Most Common |
Injection site reactions, dizziness (transient) |
| Gastrointestinal |
Nausea (rare, infusion rate-dependent) |
| CNS |
Transient headache, agitation (rare) |
| Infusion Reactions |
Flushing, sweating (rate-dependent; slow infusion reduces risk) |
| Contraindications |
Renal failure, epilepsy (caution), hypersensitivity |
| Pregnancy |
Not recommended (insufficient data) |
| Immunogenicity |
Low (well-characterized peptide fraction) |
Physicochemical Properties
| Property |
Value |
| Physical State |
Clear, colorless to slightly yellowish solution |
| pH |
6.5–7.0 (isotonic) |
| Osmolality |
~300–350 mOsm/L |
| Protein Content |
~50 mg/mL peptide fraction |
| Free Amino Acids |
~20 mg/mL (including glutamate, aspartate, glycine) |
| Na⁺ Content |
~3.54 mg/mL |
| Stability (Unopened) |
36 months at 15–25°C |
| Stability (Opened) |
Single-use only; discard unused portion |
Production Process
Cerebrolysin is a natural extract — it is not produced by synthetic peptide synthesis. The manufacturing process involves controlled enzymatic hydrolysis of standardized porcine brain tissue followed by multi-step fractionation.
| Parameter |
Detail |
| Source |
Standardized porcine brain protein hydrolysate |
| Processing |
Enzymatic hydrolysis with defined protease cocktail |
| Molecular Weight Cutoff |
≤ 10,000 Da (ultrafiltration) |
| Standardization |
Active peptide content calibrated against reference standard |
| Quality Control |
HPLC fingerprint, bioactivity assay (neurotrophic activity), endotoxin testing |
| Biological Assay |
NGF-like activity in PC12 cell bioassay |
| Sterilization |
Terminal sterile filtration (0.22 µm) and aseptic filling |
| Formulation |
Isotonic solution at pH 6.5–7.0 in nitrogen-purged ampules |
The enzymatic hydrolysis is performed using a proprietary cocktail of food-grade proteases (including trypsin-like and chymotrypsin-like activities) under controlled temperature and pH. The hydrolysate is subjected to ultrafiltration through membranes with a 10,000 Da molecular weight cutoff. The low-molecular-weight fraction is collected, concentrated, and standardized by HPLC fingerprinting against a well-characterized reference batch. Each production batch must demonstrate consistent NGF-like bioactivity in a PC12 cell neurite outgrowth assay before release.
Analytical Methods
HPLC (Peptide Fingerprinting)
🔬 AMP Peptide performs comprehensive quality control including HPLC, LC-MS, amino acid analysis, and endotoxin testing per pharmaceutical standards.
| Parameter |
Condition |
| Column |
C18 (4.6 × 250 mm, 5 μm) |
| Gradient |
5–60% B over 40 min |
| Detection |
UV 214 nm, 280 nm |
| Fingerprint |
Characteristic multi-peak profile |
Size Exclusion Chromatography (SEC)
| Parameter |
Condition |
| Column |
Superdex 30 (10 × 300 mm) |
| Mobile Phase |
0.1 M phosphate buffer, pH 7.0 |
| Detection |
UV 214 nm |
| MW Range |
120–10,000 Da |
Amino Acid Analysis
| Method |
Details |
| Hydrolysis |
6 M HCl, 110°C, 24 h |
| Derivatization |
OPA/FMOC |
| Detection |
Fluorescence |
Stability Data
| Condition |
Storage Parameters |
Stability |
| Unopened (15–25°C) |
Sealed ampule, light-protected |
36 months (manufacturer-specified) |
| Unopened (30°C) |
Sealed ampule, accelerated |
≥ 12 months (real-time data) |
| Unopened (40°C) |
Sealed ampule, stress testing |
≥ 3 months |
| Opened (2–8°C) |
Single-use ampule, sterile |
Discard immediately (no preservatives) |
| Freeze-Thaw |
Not recommended (solution formulation) |
Precipitation risk |
| Light Sensitivity |
UV/visible light exposure, 24 h |
< 5% change in HPLC fingerprint |
| pH Stability Range |
pH 5.0–8.0 |
Optimal at pH 6.5–7.0 |
| Oxidative Stress |
0.01% H₂O₂, 25°C, 1 h |
~8–12% peptide modification |
Cerebrolysin is formulated as a sterile, isotonic solution without preservatives and is intended for single use only. The product is supplied in nitrogen-purged amber glass ampules to minimize oxidative degradation. Unopened ampules maintain stability for 36 months at room temperature (15–25°C). Once opened, the solution should be used immediately and any unused portion discarded — it does not contain antimicrobial preservatives. The peptide fingerprint profile (HPLC) is the primary stability-indicating assay, with > 90% profile similarity to the reference standard required throughout the shelf life.
References
- Alvarez XA, et al. (2015). Cerebrolysin in Alzheimer's disease: a randomized, double-blind trial. Journal of Alzheimer's Disease. DOI: 10.3233/JAD-143045
- Seif-El-Nasr M, et al. (2009). Cerebrolysin attenuates cerebral ischemic injury. Brain Research Bulletin. DOI: 10.1016/j.brainresbull.2009.07.007
- Rockenstein E, et al. (2006). Cerebrolysin reduces amyloid-beta plaques. Neurobiology of Aging. DOI: 10.1016/j.neurobiolaging.2005.05.016
- Chen CC, et al. (2013). Cerebrolysin in traumatic brain injury. Journal of Neurotrauma. DOI: 10.1089/neu.2012.2566
- Masliah E, et al. (2007). Cerebrolysin effects in non-human primate model. Experimental Neurology. DOI: 10.1016/j.expneurol.2007.01.003
- Muresanu DF, et al. (2012). Cerebrolysin in neuroprotection and neuroregeneration. Journal of Neural Transmission.
- Plosker GL, et al. (2010). Cerebrolysin: a review of its use in dementia. Drugs & Aging.
🔗 AMP Peptide Product Link
Purchase Cerebrolysin wholesale from AMP Peptide